 Enzo Biochem, Inc. NYSE:ENZ, a leading biosciences and diagnostic company, today announced its Comprehensive COVID-19 Program incorporating its molecular diagnostic virus screening products, detection for immunity through IgGIgM serological ELISA products, detection of inflammation on Enzos ELISA platform, and a promising proprietary drug candidate SK1-I. Enzo is utilizing its technological and research and development capabilities, manufacturing infrastructure strength and clinical diagnostic capabilities to provide products that address gaps in performance, cost, supply obtainability and safety. Most diagnostic platforms offered by others are closed systems and have no flexibility with regards to adoptability for other infectious agents, have limited supplier relationships, and have no direct connection with the patient or the event. These underlying problems have manifested themselves in the current COVID-19 crisis. Enzos Comprehensive COVID-19 Program showcases Enzos ability to respond to the current challenges plaguing the healthcare market. 